Toward the Simultaneous Detection of Multiple Diseases with a Highly Cost-Effective Cell-Free DNA Methylome Test

Why It Matters

MethylScan lowers the financial barrier to comprehensive cfDNA testing, enabling early detection of multiple diseases from one inexpensive blood test and reshaping preventive health strategies.

Key Takeaways

• MethylScan achieved AUROC 0.938 for multicancer detection at 98% specificity
• Sensitivity 63.3% across all cancer stages, 55.3% for early-stage
• Liver cancer surveillance AUROC 0.927, 79.6% sensitivity at 90.4% specificity
• Validated on 1,061 plasma samples across five clinical use cases
• Low‑cost platform enables simultaneous disease, organ injury, and ancestry profiling

Pulse Analysis

The liquid‑biopsy market has been dominated by targeted cfDNA assays that focus on a single tumor type or a narrow set of mutations, often costing several hundred dollars per test. MethylScan disrupts this model by sequencing the entire cfDNA methylome using a streamlined, cost‑effective workflow that eliminates deep‑sequencing depth requirements. By leveraging methylation signatures that are organ‑specific, the assay captures a holistic view of tissue health, making it possible to screen for cancer, liver pathology, and organ injury simultaneously without the need for multiple separate panels.

Performance data underscore MethylScan’s clinical promise. In a diverse cohort of over a thousand participants, the test delivered an AUROC of 0.938 for detecting liver, lung, ovarian, and stomach cancers, with 63.3% sensitivity at a stringent 98% specificity—metrics that rival or exceed many FDA‑cleared multi‑cancer blood tests. For high‑risk liver cancer surveillance, the assay reached 79.6% sensitivity at 90.4% specificity, highlighting its utility in monitoring chronic disease cohorts. The same dataset demonstrated accurate liver disease classification, organ injury identification, and even ancestry inference, illustrating the assay’s breadth and the potential to consolidate disparate diagnostic workflows into a single, affordable test.

If adopted widely, MethylScan could reshape preventive medicine by making comprehensive cfDNA screening accessible to primary‑care settings and health systems focused on cost containment. Its open‑source software and publicly deposited data lower entry barriers for academic and commercial developers, fostering ecosystem growth. Regulatory pathways may be streamlined given its multi‑indication design, but real‑world validation and reimbursement strategies will be critical. As sequencing costs continue to decline, platforms like MethylScan are poised to become the backbone of next‑generation, population‑scale health monitoring.